Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

np_stocks Jul. 4 at 2:19 PM

$CTXR happy 4th except everyone that works for this shit scamming company! Have a great day. Lenny screw you, have an awful day! Where is mino-lok can we get an honest update ???

0 · Reply

yellowjacker Jul. 3 at 7:12 PM

$CTXR I have been buying CTXR because of its unqiue Portfolio. All three drugs have no other rivals. They sit in their own lane with no competition. It is also the only stock I own that insiders have a heavy position, thus, having skin in the game. Once Lymphir is sold it solves the money challenge and clears the path for Minil-ok and Halo-Lido, that will be come cash cows. The Nasdaq compliance issue is a formality. Shorts be ware.

0 · Reply

np_stocks Jul. 2 at 2:52 PM

$CTXR who buys this? SMH 🤦 … Lenny do yourself a favor and give up.

1 · Reply

JackCampbell Jul. 1 at 4:54 PM

$CTXR $CTOR for all crying about Lenny here...its really irrelevant. Relevant is that Lymphir is the one and only approved T-reg depleting therapy on the market, delivering unmatched efficacy in its class. By breaking down immune resistance, it serves as a powerful cornerstone for next-generation oncological combination therapies.$MRK $GILD and many other....

3 · Reply

np_stocks Jun. 30 at 1:22 PM

$CTXR take notes people. Mino-lok or Mino-lol.

0 · Reply

np_stocks Jun. 29 at 6:46 PM

$CTXR algorithms do yourself a favor and avoid this scam. Trying to save you some money. Company has lost investor trust for many many years. Thank me later.

0 · Reply

Bolleh Jun. 29 at 5:33 PM

$CTXR Would you please spare a penny for Lenny?

0 · Reply

np_stocks Jun. 26 at 2:41 PM

$CTXR happy Friday except this management team! Dog shit is more valuable than this…

0 · Reply

900fix Jun. 24 at 4:03 PM

$CTXR Only Lenny could f-ck this up like he did.

1 · Reply

donein12 Jun. 22 at 5:37 PM

$CTXR There is buying interest in CTXR today . Volume isn't there though. However this happened before without any follow up, whereas the price goes back down.Will it hold and comtinue to go up this time? History says no. The quarter ends in 8 days, so will there be a PR before then, and if so will it be meaningful. Needs volume for it to mean anything,do not see it as of now.

0 · Reply

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

CTOR

$Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies$

Jun 1, 2026, 7:00 AM EDT - 4 weeks ago

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

CTOR

May 26, 2026, 8:00 AM EDT - 5 weeks ago

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

CTOR

2026-05-22T21:05:10.000Z - 6 weeks ago

Citius Pharmaceuticals files to sell 5.43M shares of common stock for holders

May 22, 2026, 8:00 AM EDT - 6 weeks ago

Citius Pharmaceuticals Registration statement: Registration filing

2026-05-18T13:00:56.000Z - 6 weeks ago

Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright

May 15, 2026, 4:30 PM EDT - 7 weeks ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTOR

May 15, 2026, 4:30 PM EDT - 7 weeks ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTOR

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Citius Pharmaceuticals Quarterly report: Q2 2026

May 15, 2026, 7:00 AM EDT - 7 weeks ago

Citius Pharmaceuticals Earnings release: Q2 2026

2026-04-29T14:53:58.000Z - 2 months ago

Citius Oncology announces initial shipment of LYMPHIR to Europe

CTOR

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

CTOR

Apr 24, 2026, 4:30 PM EDT - 2 months ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

2026-04-24T12:14:18.000Z - 2 months ago

Citius Pharmaceuticals announces $5M registered direct offering priced ATM

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Mar 31, 2026, 9:11 AM EDT - 3 months ago

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

CTOR

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

CTOR

$Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers$

Mar 10, 2026, 8:47 AM EDT - 4 months ago

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

CTOR

Mar 4, 2026, 9:15 AM EST - 4 months ago

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

CTOR

2026-02-24T13:06:48.000Z - 4 months ago

Citius Pharmaceuticals receives $3.8M through NJEDA program

Feb 24, 2026, 8:00 AM EST - 4 months ago

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Feb 24, 2026, 7:00 AM EST - 4 months ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 4 months ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

2026-02-13T13:11:11.000Z - 5 months ago

Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir

CTOR

2026-02-13T13:10:44.000Z - 5 months ago

Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

CTOR

Feb 13, 2026, 8:00 AM EST - 5 months ago

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTOR

Feb 13, 2026, 8:00 AM EST - 5 months ago

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTOR

Feb 13, 2026, 7:00 AM EST - 5 months ago

Citius Pharmaceuticals Earnings release: Q1 2026

Feb 13, 2026, 7:00 AM EST - 5 months ago

Citius Pharmaceuticals Quarterly report: Q1 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

CTOR

Dec 23, 2025, 4:30 PM EST - 6 months ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Dec 23, 2025, 4:30 PM EST - 6 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Dec 23, 2025, 7:00 AM EST - 6 months ago

Citius Pharmaceuticals Earnings release: Q4 2025

Dec 23, 2025, 7:00 AM EST - 6 months ago

Citius Pharmaceuticals Annual report: Q4 2025

Dec 10, 2025, 4:30 PM EST - 7 months ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

2025-12-09T13:35:42.000Z - 7 months ago

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

CTOR

Dec 9, 2025, 8:30 AM EST - 7 months ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

Dec 4, 2025, 8:37 AM EST - 7 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTOR

Dec 1, 2025, 12:00 PM EST - 7 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTOR

Nov 25, 2025, 8:00 AM EST - 7 months ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTOR

2025-11-21T13:45:33.000Z - 8 months ago

Citius Oncology to advance launch of Lymphir with Verix AI integration

CTOR

Nov 21, 2025, 8:37 AM EST - 8 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTOR

Oct 21, 2025, 4:30 PM EDT - 9 months ago

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

2025-10-21T12:05:27.000Z - 9 months ago

Citius Pharmaceuticals announces $6M registered direct offering priced ATM

Oct 21, 2025, 8:00 AM EDT - 9 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

2025-10-20T12:40:10.000Z - 9 months ago

Citius Oncology announces distribution agreement with McKesson

CTOR MCK

Oct 17, 2025, 5:00 PM EDT - 9 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTOR

2025-10-16T12:50:19.000Z - 9 months ago

Citius Oncology signs exclusive commercialization agreement with EVERSANA

CTOR

Oct 16, 2025, 8:47 AM EDT - 9 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTOR

Sep 10, 2025, 4:30 PM EDT - 10 months ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

2025-09-09T12:38:06.000Z - 10 months ago

Citius Oncology announces pricing of $9M registered direct offering

CTOR

Sep 9, 2025, 8:30 AM EDT - 10 months ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Aug 22, 2025, 8:47 AM EDT - 11 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTOR

2025-08-12T20:36:02.000Z - 11 months ago

Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year

Aug 12, 2025, 4:30 PM EDT - 11 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Citius Pharmaceuticals Earnings release: Q3 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Citius Pharmaceuticals Quarterly report: Q3 2025

Jul 17, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTOR

Jul 16, 2025, 9:15 AM EDT - 1 year ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTOR

2025-07-15T12:49:58.000Z - 1 year ago

Citius Oncology signs distribution agreement for Lymphir with Cencora

CTOR

Jul 15, 2025, 8:32 AM EDT - 1 year ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTOR

Jul 8, 2025, 8:34 AM EDT - 1 year ago

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

2025-06-17T12:16:30.000Z - 1 year ago

Citius Oncology expects commercial launch of Lymphir in second half of 2025

CTOR

Jun 17, 2025, 8:08 AM EDT - 1 year ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTOR

Jun 12, 2025, 8:35 AM EDT - 1 year ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

2025-06-10T20:00:14.000Z - 1 year ago

Citius Pharmaceuticals price target lowered to $6 from $9 at D. Boral Capital

2025-06-10T11:11:06.000Z - 1 year ago

Citius Pharmaceuticals announces $15.8M registered direct offering

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Citius Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 12:00 AM EDT - 1 year ago

Citius Pharmaceuticals Earnings release: Q2 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Citius Pharmaceuticals Quarterly report: Q2 2025

May 5, 2025, 8:37 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 9:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTOR

Feb 14, 2025, 12:00 AM EST - 1 year ago

Citius Pharmaceuticals Quarterly report: Q1 2025

Feb 14, 2025, 12:00 AM EST - 1 year ago

Citius Pharmaceuticals Earnings release: Q1 2025

Feb 6, 2025, 8:55 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTOR

Jan 27, 2025, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Jan 16, 2025, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Jan 8, 2025, 8:00 AM EST - 1 year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTOR

Jan 6, 2025, 7:50 AM EST - 1 year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTOR

Dec 27, 2024, 5:00 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Dec 27, 2024, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Quarterly report: Q4 2024

Dec 27, 2024, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Annual report: Q4 2024

Nov 25, 2024, 8:03 AM EST - 1 year ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Nov 22, 2024, 9:00 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Nov 18, 2024, 4:05 PM EST - 1 year ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

np_stocks Jul. 4 at 2:19 PM

$CTXR happy 4th except everyone that works for this shit scamming company! Have a great day. Lenny screw you, have an awful day! Where is mino-lok can we get an honest update ???

0 · Reply

yellowjacker Jul. 3 at 7:12 PM

0 · Reply

np_stocks Jul. 2 at 2:52 PM

$CTXR who buys this? SMH 🤦 … Lenny do yourself a favor and give up.

1 · Reply

JackCampbell Jul. 1 at 4:54 PM

3 · Reply

np_stocks Jun. 30 at 1:22 PM

$CTXR take notes people. Mino-lok or Mino-lol.

0 · Reply

np_stocks Jun. 29 at 6:46 PM

$CTXR algorithms do yourself a favor and avoid this scam. Trying to save you some money. Company has lost investor trust for many many years. Thank me later.

0 · Reply

Bolleh Jun. 29 at 5:33 PM

$CTXR Would you please spare a penny for Lenny?

0 · Reply

np_stocks Jun. 26 at 2:41 PM

$CTXR happy Friday except this management team! Dog shit is more valuable than this…

0 · Reply

900fix Jun. 24 at 4:03 PM

$CTXR Only Lenny could f-ck this up like he did.

1 · Reply

donein12 Jun. 22 at 5:37 PM

0 · Reply

np_stocks Jun. 18 at 6:46 PM

$CTXR the company sucks, the stocktwits board is dead, just a sad stock and many false promises … I would just avoid completely overall and invest in solid blue chips, etfs, VOO or SPY.

0 · Reply

JackCampbell Jun. 17 at 6:05 PM

$CTXR $CTOR buyout anytime by BP because of incredible two phase 1 results (combination therapies lymphir with other oncology drugs/ t-regs)!

1 · Reply

np_stocks Jun. 17 at 2:11 PM

$CTXR stay away. A lot of disappointment and false promises. Better opportunities else where in the world. Invest in yourself like I should have.

0 · Reply

yamihere2 Jun. 17 at 3:22 AM

$CTXR Company is dead…lost more than I’d like to admit here. Absolute trash the past 5 years

0 · Reply

SweStonk Jun. 16 at 11:13 AM

$CTXR what ever anyone say here remember THIS There is ZERO cataclysts for a very long time here so there isnt anything to take this company out of the spiral of death. The only thing Mazur is able to do is a paid pump which also take SP lower than before. What we do know will happen for the coming months is more dilution because they dont have money. Being a bull or bear dont change facts. If you still believe in the scam man Mazur and want to hold or buy you should wait because of the above. If not, your shares will eventually be diluted until they are worthless. Lymphir didnt save the company as Mazur hoped it would. Spiral of death is no joke.......

1 · Reply

SweStonk Jun. 15 at 6:04 PM

$CTXR I play both sides and wouldnt be bearish if I saw light at the end of the tunnel. They cant even pay their bills. Dilution dont bring in enough money. Sales dont bring in enough money. Combination of dilution and sales dont bring in enough money. They need to do a hell of a lot dilutions to bring ML to market which will make SP collapse even more if they even are able to do more dilutions(seem to lack buyers). Then you would need to hope that ML bring in revenue which will take years. Will it even be any profit left after all the debt they have collected? Patent only last for so long. But all of this wont happen if FDA want another trial which it seem they do. Why else would it take so long for them with FDA. We are talking years for something that take couple months. How many banks do you think will loan them money? They already have big debt and 0 value. People like you delusional bulls have cost people a lot of money here tricking then to buy dogshit.

1 · Reply

JackCampbell Jun. 15 at 5:36 PM

$CTXR lol you board clown….I‘m here since a few weeks therefore I don‘t need to hit $100 but it really will be a double digit stock in a blink of an eye. Don‘t trust this clown as he‘s the real scam!

0 · Reply

yellowjacker Jun. 15 at 3:56 PM

$CTXR I only have to get to $1.70 to break even. You keep shorting and I will keep buying.

0 · Reply

900fix Jun. 15 at 2:51 PM

$CTXR SPCX has genius Elon. CTXR has dumbsh-t Lenny, who is nothing more than a mini Bernie Madoff.

0 · Reply

SweStonk Jun. 15 at 2:32 PM

$CTXR sure, Im the only one that been hitting the low and highs here for the past 5-6 years! If we followed you we would be down big and deep. Any true long here are down 98%. You need SP to hit like $100 @ share to be able to break even. After all do you still trust the numbers Mazur pull out of his ass? His timelines have been wrong with years and his lymphir estimation is tens of millions wrong. 100m first year in my ass......

0 · Reply

JackCampbell Jun. 15 at 12:45 PM

$CTXR you are the one who tries to scam here!!! one day we‘ll wake up and you‘ll be toast pre or after hours!

0 · Reply

SweStonk Jun. 14 at 11:24 PM

$CTXR Mazur scammed you all... it is clear as day now and still we have bulls that throw money at this, it is just sad. Lymphir 100m first year. One day you wont believe this was 1.7 We are 1-2 months away(3 years?) We will spin off lymphir so we dont have to pay for it. We are close we dont need to dilute. Dilute the other company. If you want to make money just short everything Mazur touches. Simple

0 · Reply

Market Cap	15.77M
Revenue (ttm)	0.00
Net Income (ttm)	-37.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	207,400
Avg Vol	709,696
Day's Range	N/A - N/A
Shares Out	27.45M
Stochastic %K	38%
Beta	0.98
Analysts	Sell
Price Target	$4.00